Morgan Stanley lowered the firm’s price target on Repare Therapeutics to $8 from $14 and keeps an Equal Weight rating on the shares. The company has multiple upcoming catalysts in 2024 that could shift investor perception, including Phase 1 MINOTAUR data evaluating lunresertib in combination with FOLFIRI and Phase 1 MAGNETIC data evaluating lunresertib in combination with gemcitabine, the analyst says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RPTX:
